Cancer Research 2010 AACR Elections 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh Jaggi, J.
Right arrow Articles by Scheinberg, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh Jaggi, J.
Right arrow Articles by Scheinberg, D. A.
[Cancer Research 65, 4888-4895, June 1, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Efforts to Control the Errant Products of a Targeted In vivo Generator

Jaspreet Singh Jaggi1, Barry J. Kappel1, Michael R. McDevitt1, George Sgouros3, Carlos D. Flombaum2, Catalina Cabassa1 and David A. Scheinberg1,2

1 Molecular Pharmacology and Chemistry Program; 2 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; and 3 Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: David Scheinberg, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-5010; Fax: 212-717-3068; E-mail: d-scheinberg{at}ski.mskcc.org.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Alpha-particle immunotherapy by targeted {alpha}-emitters or {alpha}-emitting isotope generators is a novel form of extraordinarily potent cancer therapy. A major impediment to the clinical use of targeted actinium-225 (225Ac) in vivo generators may be the radiotoxicity of the systemically released daughter radionuclides. The daughters, especially bismuth-213 (213Bi), tend to accumulate in the kidneys. We tested the efficacy of various pharmacologic agents and the effect of tumor burden in altering the pharmacokinetics of the 225Ac daughters to modify their renal uptake. Pharmacologic treatments in animals were started before i.v. administration of the HuM195-225Ac generator. 225Ac, francium-221 (221Fr), and 213Bi biodistributions were calculated in each animal at different time points after 225Ac generator injection. Oral metal chelation with 2,3-dimercapto-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P < 0.0001) in the renal 213Bi uptake; however, DMPS was more effective than DMSA (P < 0.001). The results with DMPS were also confirmed in a monkey model. The renal 213Bi and 221Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P < 0.0001). The effect on renal 213Bi activity was further enhanced by the combination of DMPS with either chlorothiazide or furosemide (P < 0.0001). Competitive antagonism by bismuth subnitrate moderately reduced the renal uptake of 213Bi. The presence of a higher target-tumor burden significantly prevented the renal 213Bi accumulation (P = 0.003), which was further reduced by DMPS treatment (P < 0.0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Radioimmunotherapy with {alpha}-particle–emitting radionuclides may have advantages because {alpha}-particles have high energies and short path lengths (50-80 µm; refs. 1, 2). Therefore, a large amount of energy is deposited over a short distance, which renders {alpha}-particles extremely cytotoxic with a high relative biological effectiveness (3–5). Little collateral damage to surrounding normal, antigen-negative cells occurs (4, 6). A single traversal of densely ionizing, high-energy {alpha}-particle radiation through the nucleus may be sufficient to kill a target cell (7). In addition, double-stranded DNA damage caused by {alpha}-particles is not easily repaired by the cells and this cytotoxicity is largely unaffected by the oxygen status and cell cycle position of the cells (1).

Among the {alpha}-emitters, we have chosen actinium-225 (225Ac), the {alpha}-emitting atomic generator, as a possible candidate for use in radioimmunotherapy. 225Ac has a sufficiently long half-life (10 days) for feasible use and it decays to stable bismuth-209 via six atoms, yielding a net of four {alpha}-particles (Fig. 1; ref. 8). We have been able to successfully couple 225Ac to internalizing monoclonal antibodies using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as the chelating moiety. The 225Ac-DOTA antibody construct acts as a tumor-selective, molecular-sized, in vivo atomic generator (targetable in vivo generator) of {alpha}-particle–emitting elements (8). The 225Ac-DOTA antibody constructs have been shown to be safe and potent antitumor agents in mouse models of solid prostatic carcinoma, disseminated lymphoma, and i.p. ovarian cancer (9, 8). The safety of 225Ac-HuM195 and 225Ac-3F8 both at low doses has been shown in primates (10). Therefore, these agents possess the potential to be used clinically in the future to treat a variety of tumor types.



View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Simplified 225Ac generator to 213Bi decay scheme, yielding four net {alpha}-particles. The half-lives are shown in italics.

 
225Ac decays via its {alpha}-emitting daughters, francium-221 (221Fr), astatine-217 (217At), and bismuth-213 (213Bi), to stable nonradioactive 209Bi (8, 11). These daughters, once formed, are unlikely to associate with the antibody-DOTA construct due to high atomic recoil-energy as a result of {alpha}-decay (12), possible rupture of the chelate, and different chemical properties of the daughters. The daughters generated and retained inside the cancer cell after internalization of the 225Ac-labeled antibody add to its cytotoxic effect (8). We have shown tumor burden as an important determinant in the biodistribution of the antibody (13, 14). However, the free daughters produced in the vasculature from the circulating unbound antibody or the antibody bound to the surface of a target cell could diffuse or be transported to various target organs, where they can accumulate and cause radiotoxicity (11). Bismuth is known to accumulate in the renal cortex (15–17). Although safe at low doses, monkeys injected with escalating doses of a nonspecific 225Ac in vivo generator developed a delayed radiation nephropathy, manifesting as anemia and renal failure (10). Therefore, a possible hindrance to the development of these agents as safe and effective cancer therapeutics is likely to be their nephrotoxicity. By preventing the renal accumulation of the radioactive daughters or by accelerating their clearance from the body, the therapeutic index of the 225Ac in vivo generator could be enhanced.

217At has the shortest half-life (32 milliseconds) of the {alpha}-emitting daughters of 225Ac. It decays almost instantaneously to 213Bi. 213Bi and 221Fr have relatively longer half-lives (45.6 and 4.9 minutes, respectively; ref. 11) and, therefore, have the potential to cause radiation damage. The presence of bismuth-binding, metallothionein-like proteins in the cytoplasm of renal proximal tubular cells makes the kidney a prime target for the accumulation of free, radioactive bismuth (15–17). Dithiol chelators have been shown to chelate bismuth and enhance its excretion in various animal, as well as human, studies (12, 18–20). 221Fr is another potentially toxic daughter of 225Ac. Francium, like sodium and potassium, is an alkali metal. Furosemide and thiazide diuretics are known to accelerate the elimination of sodium and potassium in urine by inhibiting their reabsorption in different segments of the nephron (21).

In this study, we show the effectiveness of metal chelation in scavenging and, therefore, preventing the renal accumulation of free, radioactive bismuth. We also show the value of pharmacologic inhibition of metal reabsorption in different segments of the nephron in accelerating the clearance of the radioactive 225Ac daughters. Lastly, we report the effectiveness of competitive metal blockade and the role of tumor burden in altering the pharmacokinetics and uptake of the daughter radionuclides in the kidneys. Each of these interventions could reduce the renal accumulation of 225Ac daughters.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals. Female BALB/c and severe combined immunodeficient (SCID) mice, 4 to 12 weeks of age, were obtained from Taconic (Germantown, NY). All animal studies were conducted according to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at Memorial Sloan Kettering Cancer Center.

Preparation and quality control of 225Ac-labeled antibodies. 225Ac (Oak Ridge National Laboratory, Oak Ridge, TN) was conjugated to SJ25C1 (mouse antihuman CD19 IgG1; Monoclonal Antibody Core Facility, Memorial Sloan Kettering Cancer Center) or HuM195 (humanized anti-CD33 IgG1; Protein Design Labs, Fremont, CA) using a two-step labeling method as described previously (22). Routine quality control of the labeled antibody was done using instant TLC to estimate the radiopurity and cell-binding assay to determine the immunoreactivity (9, 23).

Administration of 225Ac in vivo generator to mice. The mice were anesthetized and then injected i.v. (in retro-orbital venous plexus) with 0.5 µCi 225Ac-labeled HuM195 (for chelation, diuresis, and competitive metal blockade experiments). For the tumor burden experiments, we used 225Ac-labeled SJ25C1. The injected volume was 100 µL and the antibody dose was 6 to 8 µg per animal.

Free-metal scavenging with 2,3-dimercapto-1-propanesulfonic acid, meso-2,3-dimercaptosuccinic acid, or calcium-diethylenetriamine pentaacetate. Animals received either 2,3-dimercapto-1-propanesulfonic acid (DMPS; Sigma, St. Louis, MO) or meso-2,3-dimercaptosuccinic acid (DMSA; Sigma) in drinking water (1.2 and 1.5 mg/mL, respectively) starting 1 day before injection with 225Ac generator and continued until the animals were sacrificed. The control animals received regular drinking water. The water bottles were replaced with fresh DMPS or regular water every 12 hours. The average water consumption was slightly lower in the DMPS-treated group (3.5 mL/mouse/d) compared with control animals (4 mL/mouse/d). For i.p. chelation therapy, 1.2 mg calcium-diethylenetriamine pentaacetate (Ca-DTPA) or DMPS was administered per animal in 2-hourly divided doses over 24 hours. Animals (five per group) were sacrificed at different time points postinjection by carbon dioxide asphyxiation, and samples of blood (by cardiac puncture) and kidneys were removed. The organs were washed in distilled water, blotted dry on gauze, weighed, and the activities of 221Fr (185-250 keV window) and 213Bi (360-480 keV window) were measured using a gamma counter (COBRA II, Packard Instrument Company, Meriden, CT). Samples of the injectate (100 µL) were used as decay correction standards. Adjustment was made for the small percentage of bismuth activity that counted in the francium activity window. Percentage injected dose of 225Ac, 221Fr, and 213Bi per gram of tissue weight (%ID/g) was calculated for each animal at the time of sacrifice, using the equation described previously (24). The mean %ID/g was determined for each experimental group.

Scavenging of free metal in monkeys. Male cynomolgus monkeys (n = 2), weighing 7 to 8 kg, were injected i.v. with 22.5 µCi 225Ac-labeled antibody (HuM 195). The treated animal received DMPS in drinking water (1.2 mg/mL) and was injected i.v. with 200 mg DMPS (Heyl, Berlin, Germany) 90 minutes before sacrifice. The control animal received regular drinking water. The monkeys were sacrificed 24 hours postinjection with 225Ac-labeled antibody. Percentage injected dose of 225Ac, 221Fr, and 213Bi per gram of blood and kidneys (%ID/g) at the time of sacrifice was calculated for both monkeys as described above.

Intra-peritoneal hydration in mice. The mice were randomized to receive either 1 mL normal saline i.p. every 12 hours or no treatment (control group). Mice (four animals per group) were sacrificed at 24 and 192 hours after 225Ac in vivo generator injection. The mean activity of actinium, francium, and bismuth per gram (%ID/g) in blood and kidneys was determined for hydration and control group. To evaluate the effect of hydration on blood clearance of the parent drug ([225Ac]HuM195), mice received either hydration (1 mL normal saline i.p. every 12 hours) or no hydration. Four to six mice from each group were bled from the retro-orbital venous plexus at 1, 4, 24, 120, and 192 hours after injection with the Ac-labeled antibody. The percentage injected dose of actinium per gram of blood was calculated for each animal. The mean %ID/g in blood was determined for the hydration treatment and control group and plotted against time.

Forced diuresis in mice. In one study, mice were randomized to furosemide treatment, chlorthiazide treatment, or no treatment (control) groups. Furosemide and chlorothiazide were administered i.p. The loading doses of furosemide and chlorothiazide were 250 and 750 mg/kg, respectively, administered 1 hour before 225Ac in vivo generator injection. The maintenance doses were 100 and 300 mg/kg, respectively, administered 12 and 24 hours after the loading dose. The controls were injected with an equal volume of saline (vehicle). In another study, mice received DMPS (1.2 mg/mL in drinking water) and either furosemide or chlorothiazide i.p. (same dose schedule as above). The controls received regular drinking water and were injected with equal volume of saline. To study the effect of a potassium-sparing diuretic on daughter excretion, mice received either a s.c. sustained time release (1.1 mg/d) spironolactone pellet (Innovative Research of America, Sarasota, FL), implanted 12 hours preinjection with 225Ac in vivo generator, or no treatment (controls). Animals (five per group) were sacrificed at 24 hours postinjection with the labeled antibody and the mean activity (%ID/g) of 225Ac, 221Fr, and 213Bi in blood and kidneys was calculated for each experimental group.

Competitive metal blockade studies. Mice were injected i.p. with 200 µL 1% bismuth subnitrate suspension (100 mg/kg; Sigma) 4 hours before 225Ac in vivo generator injection (n = 5; sacrificed at 6 hours postinjection with 225Ac in vivo generator) or 4 hours before and 8 and 20 hours after 225Ac in vivo generator injection (n = 5; sacrificed at 24 hours postinjection). Controls (n = 10) received an equal volume of saline (vehicle) i.p. and five animals were sacrificed at 6 and 24 hours postinjection. In another experiment, mice received either 200 µL of 10 mg/mL ferric ammonium citrate solution (Sigma) or saline (vehicle) i.p. 1 hour before 225Ac in vivo generator injection. The animals were sacrificed 24 hours postinjection. The mean activity (%ID/g) of actinium, francium, and bismuth in blood and kidneys at sacrifice time was estimated for each experimental group.

Tumor burden experiments. Disseminated human Daudi lymphoma (25) treated with 225Ac-labeled anti-CD19 was used as the model system. SCID mice, 10 to 12 weeks old, were randomized to "low tumor burden" group (7 days growth of tumor), "high tumor burden" group (30 days growth of tumor), or "high tumor burden + DMPS" group (30 days growth of tumor and treated with 1.2 mg/mL DMPS in drinking water starting 1 day before injection with 225Ac in vivo generator). All mice were injected i.v. with 5 x 106 Daudi lymphoma cells in 0.1 mL PBS. The "low-burden" animals were injected with the tumor cells 23 days after the "high-burden" ones. The animals were checked daily for the onset of hind leg paralysis. Thirty days after injection of tumor cells in the high-burden animals (7 days for the low-burden group), all animals were injected retro-orbitally with 0.5 µCi 225Ac-labeled SJ25C1 in 100 µL. The animals (five per group) were sacrificed at 24 hours postinjection, and the mean 225Ac, 221Fr, and 213Bi activity (%ID/g) in blood, femurs, and kidneys was calculated for each experimental group. The percentage of human CD20–positive cells in the femoral bone marrow was estimated in one representative animal from the high- and low-burden groups by flow cytometric staining with phycoerythrin-conjugated antihuman CD20 (BD Biosciences, San Jose, CA) and compared with that of a nontumor-bearing mouse of the same strain.

Estimation of renal absorbed dose. The renal 225Ac, 221Fr, and 213Bi activity (%ID/g) at various time points (to 8 days) postinjection with 225Ac-labeled HuM195 was used to estimate the renal absorbed dose. The mean absorbed dose to the kidneys was estimated by assuming that all {alpha}-particle energy emitted by decays within the kidneys is absorbed within the kidneys. A biexponential expression, A1e–{lambda}1t + A2e–{lambda}2t, was fitted to the renal time versus 225Ac activity curve using the Simulation Analysis and Modeling software package, SAAM II (SAAM Institute, Inc., Seattle, WA; ref. 10). The resulting expression was analytically integrated to 8 days (192 hours) and to infinity to obtain the number of 225Ac decays in the kidneys over 8 days and the total number of decays, respectively. Biexponential expressions were also fitted to the kidney time-activity curves for 221Fr and 213Bi. The resulting expressions were integrated over the measurement period of 8 days. The total number of decays of these two daughters was obtained by scaling the estimated decays for each daughter during the data collection period by the ratio of total 225Ac decays to 225Ac decays estimated during the 8-day measurement period. This approach assumes that the daughter radionuclides produced by 225Ac decay will continue to concentrate in the kidneys at the ratio observed over the first 8 days. Because of its short (32 milliseconds) half-life and the correspondingly low probability of its leaving the kidneys, the number of 217At decays in the kidneys was assumed equal to 221Fr decays. The absorbed dose to the kidneys was obtained as the sum of the dose contribution from each daughter. The dose contribution from each daughter was calculated as the product of the number of decays per gram multiplied by the {alpha}-particle energy emitted per decay; photon and electron contributions to the absorbed dose were considered negligible relative to the {alpha}-particle dose.

Statistical analysis. Graphs were constructed using Prism (Graphpad software, Inc., San Diego, CA). Statistical comparisons between the experimental groups were done by either the Student's t test (two-group comparison) or one-way ANOVA with Bonferroni's multiple comparison post hoc test (three-group comparison). All statistical comparisons were two sided and the level of statistical significance was set at P < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Reduction in the renal 213Bi activity by metal scavenging. The renal 213Bi activity was significantly lower in DMPS- or DMSA-treated animals compared with untreated controls at 6 hours (ANOVA, P < 0.0001), 24 hours (ANOVA, P < 0.0001), and 72 hours (ANOVA, P < 0.0001) postinjection with the 225Ac in vivo generator (Fig. 2A; Table 1). DMPS was significantly more effective than DMSA in preventing the renal 213Bi accumulation at each time point (6 hours, P < 0.001; 24 hours, P < 0.001; 72 hours, P < 0.001). The renal 221Fr activity, however, was not significantly different between the experimental groups at either 6 hours (ANOVA, P = 0.39), 24 hours (ANOVA, P = 0.42), or 72 hours (ANOVA, P = 0.20) postinjection. As shown in Fig. 2B, the mean blood 213Bi activity was higher in the DMPS- and DMSA-treated groups compared with the controls (6 hours, ANOVA, P < 0.0001; 24 hours, ANOVA, P < 0.0001; 72 hours, ANOVA, P < 0.0001). Ca-DTPA treatment significantly prevented the renal 213Bi accumulation (Fig. 2C), but it was less potent than DMPS in doing so [mean difference = 10.13; 95% confidence interval (95% CI), 5.48-14.77; P < 0.0001]. Similar experiments conducted up to 8 days postinjection with the radiolabeled antibody showed similar reduction (58.4%, 65.3%, and 60.7% at 120, 144, and 192 hours, respectively) in the renal bismuth activity, thus confirming the results obtained at early time points.



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Effect of heavy metal chelators on 221Fr and 213Bi distribution in kidneys and blood. A, reduction in the renal 213Bi activity by DMPS or DMSA treatment at 6, 24, and 72 hours postinjection. B, increase in the 213Bi activity in blood by chelation therapy with DMPS or DMSA. C, comparison of the potencies of Ca-DTPA and DMPS in reducing in the renal 213Bi accumulation at 24 hours postinjection. D, reduction in the 24-hour renal 213Bi activity in a DMPS-treated cynomolgus monkey compared with an untreated animal. Columns, mean; bars, 95% CI. %ID/g, percentage of injected dose per gram of tissue.

 

View this table:
[in this window]
[in a new window]

  		Table 1. Reduction in the renal 213Bi activity by chelation therapy

 
To test and confirm our hypothesis and result in an animal model more similar to humans, we also tested the effects of DMPS in a single monkey treated with DMPS compared with an untreated control monkey. The renal 213Bi activity was lower in the DMPS-treated monkey (Fig. 2D) compared with the untreated one (0.08 and 0.33 %ID/g, respectively). However, the renal and blood 221Fr and 225Ac activities were unaltered by DMPS treatment (data not shown). Because this single experiment directly confirmed the results in mice, additional monkeys were not tested for ethical reasons.

Lack of an effect of hydration on 225Ac daughter distribution and [225Ac]HuM195 blood clearance. Renal activity of 213Bi and 221Fr was significantly lower at 192 hours compared with 24 hours postinjection (Fig. 3A). The renal distribution of 213Bi and 221Fr was not significantly altered by hydration at either 24 hours (213Bi activity, mean difference = 2.78; 95% CI, –2.30-7.85; P = 0.23; 221Fr activity, mean difference = 2.00; 95% CI, –1.05-5.05; P = 0.16) or 192 hours postinjection (213Bi activity, mean difference = 3.90; 95% CI, –0.93-8.73; P = 0.09; 221Fr activity, mean difference, 0.93; 95% CI, –0.84-2.70; P = 0.23). The blood 213Bi and 221Fr activity was also similar in the two groups (data not shown). After i.v. administration in mice, [225Ac]HuM195 displayed a biphasic clearance from the blood with ~85% of the 225Ac activity clearing rapidly within the first 24 hours and a slower clearance thereafter. The blood clearance of the labeled antibody was not significantly altered by hydration (Fig. 3B).



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Effect of hydration, diuresis, or a combination of metal chelation and diuresis on renal 221Fr and 213Bi activity. A, renal 221Fr and 213Bi activity in saline hydrated or control mice at 24 and 192 hours postinjection. B, plasma clearance of the radioimmunoconjugate estimated by serial blood sampling from the retro-orbital venous plexus 1, 6, 24, 48, 120, and 192 hours (four to six animals per group at each time point) postinjection. Mice received i.p. saline or no treatment (controls). C, reduction in the 24-hour renal 221Fr and 213Bi activities by furosemide and chlorothiazide (CTZ) treatment. D, reduced renal accumulation of 221Fr and 213Bi at 24 hours postinjection by combination therapy with DMPS and furosemide or chlorothiazide. Columns, mean; bars, 95% CI.

 
Prevention of renal 221Fr and 213Bi accumulation by diuretic therapy. In contrast to metal chelation, diuretic therapy prevented the renal accumulation of both 221Fr and 213Bi (Fig. 3C; Table 2). The 24-hour renal 213Bi activity was significantly lowered by furosemide and chlorothiazide treatment (ANOVA, P < 0.0001). In addition, 24-hour renal 221Fr activity was also significantly reduced (ANOVA, P < 0.0001) in furosemide- and chlorothiazide-treated groups compared with untreated controls. However, the renal 221Fr and 213Bi activities were not significantly different between the two diuretic treated groups (Bonferroni's post hoc analysis, P > 0.05 for both 221Fr and 213Bi activities; Fig. 3C; Table 2).


View this table:
[in this window]
[in a new window]

  		Table 2. Reduction in the 24-hour renal 221Fr and 213Bi activities by diuretic treatment

 
The combination of DMPS with a diuretic (furosemide or chlorothiazide) caused a greater reduction (~75-80%) in the renal 213Bi activity than seen with DMPS or diuretic therapy alone (Fig. 3D; Table 3). The reduction in the renal 221Fr accumulation, however, was similar to that seen with diuretic treatment.


View this table:
[in this window]
[in a new window]

  		Table 3. NOTE: Reduction in the 24-hour renal 221Fr and 213Bi activities by a combination of chelation and diuretic therapy

 
Spironolactone, a potassium sparing diuretic, had no significant effect on the renal 221Fr (mean difference = 1.84; 95% CI, –0.22-3.90; P = 0.07) and 213Bi (mean difference = 2.56; 95% CI, –3.43-8.55; P = 0.35) accumulation compared with controls.

Effect of cold metal blockade on renal accumulation of 213Bi. Competitive blockade of 213Bi binding sites in the renal tubular cells by nonradioactive bismuth resulted in a moderate but significant reduction in the renal 213Bi activity at both 6 hours (mean difference = 11.32; 95% CI, 4.81-17.83; P = 0.004) and 24 hours (mean difference = 16.70; 95% CI, 13.65-19.75; P < 0.0001) time points (Fig. 4A). As expected, the renal 221Fr activity was unaltered at either time point (6 hours, P = 0.10; 24 hours, P = 0.61). In contrast, blockade of 213Bi binding sites in blood by ferric ammonium citrate had no significant impact on 24-hour renal 221Fr (P = 0.34) or 213Bi (P = 0.28) activities (Fig. 4B).



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Effect of competitive metal blockade on 225Ac daughter distribution. A, reduction in the renal 213Bi activity by bismuth subnitrate (BSN) at 6 and 24 hours postinjection. B, 221Fr and 213Bi activity in the kidneys of control and ferric ammonium citrate (FAC)–treated animals at 24 hours postinjection. Bars, 95% CI.

 
Role of tumor burden in altering the pharmacokinetics of [225Ac]SJ25C1 and 225Ac daughters. We evaluated the role of tumor burden and the effect of DMPS in a disseminated Daudi lymphoma model system. The expression of CD19 and CD20 antigens and binding of the antibody (SJ25C1) to CD19 on Daudi cells were confirmed by flow cytometry before injecting the tumor cells in animals. Flow cytometric analysis was done in a single animal to show that the tumor growth occurred within this time period. The percentage of target lymphoma cells (bone marrow cells positive for human CD20) in one representative low-burden mouse was 0.12% and was 27% in a high-burden animal. Five animals were examined for biodistribution in each group. Due to higher localization of the labeled antibody (225Ac activity) to the lymphoma cells in the femurs (Fig. 5A), the kidney-to-femur activity ratio for 225Ac was significantly lower in the group with higher tumor burden compared with low tumor burden group (mean difference = 0.57; 95% CI, 0.31-0.83; P < 0.0001; Fig. 5B). As shown in Fig. 5C, the presence of a higher tumor burden resulted in a significant decrease in the renal 213Bi activity (mean difference = 13.68; 95% CI, 4.40-22.96; P = 0.003). This amount was further reduced by DMPS treatment (mean difference = 22.26; 95% CI, 12.98-31.54; P < 0.001 compared with untreated high-burden group and mean difference = 35.94; 95% CI, 26.66-45.22; P < 0.001 compared with low-burden group). However, DMPS also reduced the 213Bi activity in the femurs (by 43.1%) to a slightly lower degree than in the kidneys (by 58.4%). The femur 213Bi activity was significantly higher in the untreated high-burden group compared with the low-burden group (mean difference = 5.82; 95% CI, 3.87-7.77; P < 0.001). The ratio of kidney to femur activity for 213Bi was significantly lower in the groups with higher tumor burden (low-burden versus untreated high-burden group, mean difference = 15.33; 95% CI, 11.80-18.86; P < 0.0001; Fig. 5B).



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Effect of tumor burden on 225Ac daughter distribution. A, alteration in the distribution of 225Ac-labeled antibody in animals with a higher tumor burden compared with those with lower tumor burden. B, reduction in the ratio of kidney to femur activity for 225Ac and 213Bi in animals with higher versus lower tumor burden. DMPS treatment further reduced the kidney-to-femur activity ratio for 213Bi. C, reduction in the renal 213Bi activity by the presence of higher tumor burden and further enhancement of the effect by concomitant DMPS treatment. Bars, 95% CI.

 
Renal dosimetry. The estimated absorbed dose to mice kidneys after injection with 0.35 µCi [225Ac]HuM195 is 27.6 Gy; with absorbed dose contributions of 0.6, 7.1, 7.9, and 12 Gy from 225Ac, 221Fr, 217At, and 213Bi, respectively. The estimated renal dose following chelation therapy is 19.6 Gy due to a reduction in the 213Bi dose from 12 to 4 Gy. Diuresis with chlorothiazide or furosemide reduces the renal dose estimates from 221Fr, 217At, and 213Bi to 3.2, 3.6, and 6 Gy, respectively (total dose = 13.4 Gy). A combination of chelation and diuresis reduces the estimated renal absorbed dose to 9 Gy with contributions from 221Fr, 217At, and 213Bi being 2.8, 3.1, and 2.5 Gy, respectively.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Radioimmunotherapy has advanced tremendously in the last 20 years with the development of more sophisticated carrier molecules and radionuclides with emission characteristics, half-lives, and chemical properties suited to a particular cancer and therapeutic application (26, 27). High–linear energy transfer, short path length {alpha}-particles can mediate efficient and selective cell kill with little nonspecific cytotoxicity (2–6, 28, 29). The results of preclinical studies with antibody-targeted, {alpha}-particle–emitting 225Ac in vivo generators have generated optimism as well as caution for their potential human clinical use (8, 9). The advantage of using 225Ac is its relatively long half-life (10 days) compared with other {alpha}-particle–emitting radionuclides used for radioimmunotherapy in humans (213Bi, t1/2 = 45.6 minutes; 211At, t1/2 = 7.2 hours; refs. 29, 30). This permits delivery of radiation even to the less readily accessible cells (8).

225Ac decays sequentially through three {alpha}-particle–emitting daughters (221At, 217Fr, 213Bi) to yield a net of four {alpha}-particles. Although this property greatly enhances the potency of the 225Ac in vivo generators, it also results in increased toxicity as the systemically released radioactive daughters may get transported to and irradiate the normal tissues. The 225Ac immunoconjugate is stable in vivo and the daughters released inside the target cell remain internalized (8). However, the daughters released from the circulating 225Ac in vivo generator tend to distribute independently of the parent construct (10).

In the model here, we picked kidneys as the primary target organ for our studies for two reasons. First, 213Bi, potentially the most toxic 225Ac daughter, tends to accumulate preferentially in the kidneys (15–17, 19). In addition, francium, an alkali metal like sodium and potassium, can possibly accumulate in renal tubular cells. Second, the results from our toxicity studies in monkeys injected with high doses of antibody-225Ac suggest delayed nephropathy progressing to renal failure as the cause of severe morbidity in these animals (10).

We tested several pharmacologic approaches and the role of tumor burden in preventing the renal accumulation of 225Ac daughter nuclides. The dithiol chelators, DMPS and DMSA, are known to chelate and enhance the urinary excretion of bismuth (12, 18–20,). Ca-DTPA has been used in the United States as a chelating agent for plutonium and other transuranic elements (31, 32). In our studies, each of these chelators significantly reduced the renal 213Bi accumulation. However, DMPS was the most efficacious agent at all the time points.

In human plasma, DMPS has been shown to form nonprotein sulfhydryls to a greater extent (37%) than DMSA (8%; ref. 33). Therefore, DMPS is thought to be more reactive in plasma than DMSA (33). This may account for the greater effectiveness of DMPS in the studies here in reducing the renal 213Bi uptake compared with DMSA. DMPS gets rapidly oxidized in aqueous solutions to form disulfides (34). We, however, did not see a loss of efficacy when it was administered in drinking water compared with parenteral administration. This is possibly due to disulfide reduction in the renal tubular cells by a glutathione-disulfide exchange reaction to yield the parent drug (33).

The mechanism for the increase in the blood 213Bi activity with chelation therapy may be related to the chelation and retention of 213Bi generated in blood from the circulating 225Ac in vivo generators or the extraction of tissue 213Bi into the blood stream. However, we did not see an increase in the whole body retention of 213Bi. The consequences of increased blood dose are not known. The circulating chelator-213Bi complex may not cause any significant toxicity due to the short path length of {alpha}-particles. In the clinical trial with 213Bi-labeled HuM195, {alpha}-particle irradiation in blood was not associated with significant toxicity for injections of up to 100 mCi 213Bi (30). In contrast, any reduction in the renal 213Bi activity is likely to improve the safety of the 225Ac in vivo generators.

Although hydration can increase the renal plasma flow and glomerular filtration rate via an increase in the intravascular volume, the filtered load (product of the glomerular filtration rate and the plasma concentration) of 213Bi and 221Fr could remain unchanged as the plasma concentrations of the daughters decrease with an increase in blood volume. Therefore, in the absence of an intervention to limit the tubular reabsorption of the 213Bi and 221Fr, their excretion was not enhanced by hydration alone.

Different classes of diuretics inhibit the tubular reabsorption of the alkali metals, Na+ or K+ or both, although they differ in their potency, mechanism, and site of action within the nephron. Furosemide and chlorothiazide act in the ascending limb of Henle's loop and distal convoluted tubule of the nephron, respectively (35). The significant drop in the renal 221Fr activity with furosemide and chlorothiazide is possibly due to an inhibition of the renal tubular reabsorption of 221Fr, which is an alkali metal and is, therefore, expected to behave like Na+ and K+. Because 213Bi is generated from 221Fr, a decrease in the renal 213Bi ensued. Furthermore, the combination of DMPS with a diuretic (furosemide or chlorothiazide) resulted in an even greater reduction in renal 213Bi activity than seen with DMPS or the diuretics alone. The absence of an effect of spironolactone, a potassium-sparing diuretic, on renal 213Bi and 221Fr activity can be explained by its low potency (35). The administered doses of furosemide and chlorothiazide were scaled from previously published literature on their ED50 in mice. The doses exceed the human therapeutic doses as there is a species difference in the ED50 of these drugs (36).

Bismuth is both filtered as well as secreted because the renal clearance of bismuth is greater than that of inulin (15). It is believed that ionized bismuth (Bi3+) is bound to the plasma proteins and forms a slow-clearing compartment (15). We attempted to competitively limit the number of available binding sites for 213Bi on transferrin (37) by use of ferric ammonium citrate. This strategy was expected to increase the amount of unbound 213Bi in the plasma and, therefore, accelerate its excretion via kidneys. The absence of a significant enhancement of 213Bi excretion may be due to the binding of the 213Bi to albumin (38) when the binding sites on transferrin were blocked by ferric ammonium citrate. In contrast, competitive blockade of either 213Bi uptake or its binding sites (metallothionein-like proteins) in the renal tubular cells (16, 17) by nonradioactive bismuth subnitrate significantly reduced the accumulation of 213Bi in the kidneys at both 6 and 24 hours postinjection.

The daughters released after internalization of the labeled antibody are retained inside the target cells (8). The presence of high levels of a specific target (tumor burden) caused a decrease in the amount of circulating, untargeted antibody and, therefore, the systemically released daughters. This translated to an increase in the activity of 225Ac and its radioactive daughters in the femurs (where the tumor resided) and a corresponding decrease in their activities in the kidneys. This positive effect may have been blunted by the large dose of antibody used and the low specific activity of the radioimmunoconjugate as ~1 of 1,000 antibodies were labeled with 225Ac. Based on the number of available CD19 sites per Daudi cell, 120 x 106 tumor cells (estimated tumor load in a high-burden animal) are expected to maximally absorb ~1.2 µg of the antibody, whereas 6.7 µg of the antibody was injected per animal. This translates to an excess of injected antibodies compared with the available binding sites. In contrast, in a typical acute myeloid leukemia patient with ~1012 leukemia cells, ~5 mg HuM195 could be absorbed, which is a typical dose of this antibody in humans (30). At these antibody doses, a more pronounced reduction in the renal daughter accumulation could be expected.

DMPS treatment further reduced the renal 213Bi accumulation in animals that bore the target tumor. Additionally, a reduction in the femur 213Bi activity was seen in these animals. However, despite the reduction in the 213Bi activity in the femurs, the kidney-to-femur activity ratio in these animals for 213Bi was significantly lower. This is because of a greater relative reduction in the 213Bi accumulation in kidneys than in the femurs. Free bismuth has been shown to accumulate in the femurs even in the absence of a bone marrow tumor (12). Therefore, the 213Bi activity in the femurs cannot be entirely accounted for by the 213Bi inside the tumor cells. The reduction in the femur 213Bi activity may be due to its scavenging from the tumor cells or the femurs. It could also be due to scavenging of free 213Bi produced on the surface of the tumor cells as a result of the attachment of the labeled antibody. Furthermore, three {alpha}-particle emissions would have occurred in the target cell before 213Bi is formed. However, a possible reduction in the antileukemia activity is possible.

The doses of DMPS used in our studies are in the recommended 0.1 to 1 mmol/kg/d range for the treatment of heavy metal poisoning (12). Although the effective half-lives of many radiolabeled antibodies in humans are usually measured in several days, the 10-day half-life of 225Ac and continuous generation of daughters may require that patients treated with 225Ac in vivo generator be administered chelation therapy for a relatively longer period. DMPS has been shown to be safe when used long term (months) for heavy metal detoxification trials in humans (39, 40). The interexperimental variance in the tissue daughter activities at a given time point was expected owing to possible age-related variability in the capacity of the reticuloendothelial system to metabolize the labeled antibody. However, the intraexperimental variability within an experimental group was small.

A uniform distribution of {alpha}-particle energy was assumed in the calculations for the renal absorbed dose. In the absence of detailed microdistribution data, these estimates are an oversimplification considering the high energy and short path-length of {alpha}-particles. The results are presented in units of Gy rather than Sv because the exact relative biological effectiveness value of {alpha}-particles for kidney cells in vivo is not known. Radiation-induced decrease in renal function is a late change and may take months to years to manifest (41). In comparison with other species, mouse kidneys are relatively radioresistant and exhibit radiation-induced renal injury at a much later time point (41). Therefore, the impact of these pharmacologic interventions on long-term survival is difficult to assess in mice. However, because the development of radiation nephropathy is dose-dependent (41), we speculate that a reduction in the radiation dose to the kidneys might be beneficial. Proof of this hypothesis will require long-term primate or human studies, which are planned.

In summary, we tested the value of different pharmacologic agents and the role of tumor burden in altering the pharmacokinetics of the 225Ac-labeled antibody and the released decay daughters. The results suggest that chelation and diuretic therapy, alone or in combination, and competitive metal blockade to a certain extent can reduce the renal accumulation of 225Ac daughters. Therefore, these approaches could possibly enhance the therapeutic index of the 225Ac immunoconjugates. The findings support the use of dithiol chelators, thiazide diuretics, and furosemide as possible adjuvants for future clinical trials with 225Ac in vivo generators.


   Acknowledgments
 
Grant support: NIH grants R01-CA 55349 and P01-33049 (Bethesda, MD); Joseph LeRoy and Ann C. Warner Fund; William and Alice Goodwin Commonwealth Foundation for Cancer Research; and Actinium Pharmaceuticals, Inc.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: D. Scheinberg is a Doris Duke Distinguished Clinical Scientist.

Received 8/27/04. Revised 3/ 8/05. Accepted 3/16/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553–63.[Abstract/Free Full Text]
  2. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: {alpha}-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci U S A 1986;83:474–8.[Abstract/Free Full Text]
  3. Bethge WA, Wilbur DS, Storb R, et al. Selective T-cell ablation with bismuth-213-labeled anti-TCR{alpha}ß as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003;101:5068–75.[Abstract/Free Full Text]
  4. Hassfjell S, Brechbiel MW. The development of the {alpha}-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev 2001;101:2019–36.[CrossRef][Medline]
  5. Yao Z, Garmestani K, Wong KJ, et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 2001;42:1538–44.[Abstract/Free Full Text]
  6. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269–77.[CrossRef][Medline]
  7. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of {alpha} particles. III. Cell inactivation by {alpha}-particle traversals of the cell nucleus. Radiat Res 1991;128:204–9.[Medline]
  8. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537–40.[Abstract/Free Full Text]
  9. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084–90.[Abstract/Free Full Text]
  10. Meiderer M, McDevitt MR, Sgouros G, Kramer K, Cheung N, Scheinberg DA. Pharmacokinetics, dosimetry and toxicity of the targetable atomic generator, Actinium-225-HuM195 in non-human primates. J Nucl Med 2004;45:129–37.
  11. Davis IA, Glowienka KA, Boll RA, et al. Comparison of 225actinium chelates: tissue distribution and radiotoxicity. Nucl Med Biol 1999;26:581–9.[CrossRef][Medline]
  12. Jones SB, Tiffany LJ, Garmestani K, Gansow OA, Kozak RW. Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth {alpha} radioimmunotherapy. Nucl Med Biol 1996;23:105–13.[CrossRef][Medline]
  13. Scheinberg DA, Straus DJ, Yeh SD, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 1990;8:792–803.[Abstract]
  14. Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993;34:422–30.[Abstract/Free Full Text]
  15. Russ GA, Bigler RE, Tilbury RS, Woodard HQ, Laughlin JS. Metabolic studies with radiobismuth. I. Retention and distribution of 206Bi in the normal rat. Radiat Res 1975;63:443–54.[CrossRef][Medline]
  16. Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp 1989;4:303–23.[Medline]
  17. Szymanska JA, Mogilnicka EM, Kaszper BW. Binding of bismuth in the kidneys of the rat: the role of metallothionein-like proteins. Biochem Pharmacol 1977;26:257–8.[CrossRef][Medline]
  18. Basinger MA, Jones MM, McCroskey SA. Antidotes for acute bismuth intoxication. J Toxicol Clin Toxicol 1983;20:159–65.[Medline]
  19. Slikkerveer A, Jong HB, Helmich RB, de Wolff FA. Development of a therapeutic procedure for bismuth intoxication with chelating agents. J Lab Clin Med 1992;119:529–37.[Medline]
  20. Slikkerveer A, Noach LA, Tytgat GN, Van der Voet GB, De Wolff FA. Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid. Analyst 1998;123:91–2.[Medline]
  21. Reyes AJ, Taylor SH. Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther 1999;13:371–98.[CrossRef][Medline]
  22. McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002;57:841–7.[CrossRef][Medline]
  23. Nikula TK, McDevitt MR, Finn RD, et al. {alpha}-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40:166–76.[Abstract/Free Full Text]
  24. Mirzadeh S, Kumar K, Gansow OA. The chemical fate of 212Bi-DOTA formed by ß-decay of 212Pb(DOTA)2-. Radiochim Acta 1993;60:1–10.
  25. Ghetie MA, Picker LJ, Richardson JA, Tucker K, Uhr JW, Vitetta ES. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994;83:1329–36.[Abstract/Free Full Text]
  26. McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ 2002;9:593–4.[CrossRef][Medline]
  27. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488–99.[CrossRef][Medline]
  28. Mulford DA, Jurcic JG. Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther 2004;4:95–105.[CrossRef][Medline]
  29. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted {alpha}-particle radiotherapy. Curr Pharm Des 2000;6:1433–55.[CrossRef][Medline]
  30. Jurcic JG, Larson SM, Sgouros G, et al. Targeted {alpha} particle immunotherapy for myeloid leukemia. Blood 2002;100:1233–9.[Abstract/Free Full Text]
  31. Breitenstein BD Jr, Fry SA, Lushbaugh CC. The U.S. Experience 1958-1987, In: The medical basis of radiation accident preparedness. 2nd ed. New York: Elsevier Science Publishing Co., Inc. 1990. p. 397–406.
  32. Bruenger FW, Taylor DM, Taylor GN, Lloyd RD. Effectiveness of DTPA treatments following the injection of particulate plutonium. Int J Radiat Biol 1991;60:803–18.[Medline]
  33. Maiorino RM, Xu ZF, Aposhian HV. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J Pharmacol Exp Ther 1996;277:375–84.[Abstract/Free Full Text]
  34. Aposhian HV, Mershon MM, Brinkley FB, Hsu CA, Hackley BE. Anti-lewisite activity and stability of meso-dimercaptosuccinic acid and 2,3-dimercapto-1-propanesulfonic acid. Life Sci 1982;31:2149–56.[CrossRef][Medline]
  35. Puschett JB. Pharmacological classification and renal actions of diuretics. Cardiology 1994;84(Suppl 2):4–13.
  36. Hesdorffer DC, Stables JP, Hauser WA, Annegers JF, Cascino G. Are certain diuretics also anticonvulsants? Ann Neurol 2001;50:458–62.[CrossRef][Medline]
  37. Sun H, Li H, Mason AB, Woodworth RC, Sadler PJ. Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem 2001;276:8829–35.[Abstract/Free Full Text]
  38. Sun H, Szeto KY. Binding of bismuth to serum proteins: implication for targets of Bi(III) in blood plasma. J Inorg Biochem 2003;94:114–20.[CrossRef][Medline]
  39. Guha Mazumder DN, De BK, Santra A, et al. Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. J Toxicol Clin Toxicol 2001;39:665–74.[CrossRef][Medline]
  40. Guha Mazumder DN, Ghoshal UC, Saha J, et al. Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. J Toxicol Clin Toxicol 1998;36:683–90.[Medline]
  41. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol 2003;23:486–99.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
H. Song, R. F. Hobbs, R. Vajravelu, D. L. Huso, C. Esaias, C. Apostolidis, A. Morgenstern, and G. Sgouros
Radioimmunotherapy of Breast Cancer Metastases with {alpha}-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
Cancer Res., December 1, 2009; 69(23): 8941 - 8948.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Miederer, G. Henriksen, A. Alke, I. Mossbrugger, L. Quintanilla-Martinez, R. Senekowitsch-Schmidtke, and M. Essler
Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
Clin. Cancer Res., June 1, 2008; 14(11): 3555 - 3561.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Robinson, C. Shaller, K. Garmestani, P. S. Plascjak, K. M. Hodge, Q.-A. Yuan, J. D. Marks, T. A. Waldmann, M. W. Brechbiel, and G. P. Adams
Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the {alpha}-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies
Clin. Cancer Res., February 1, 2008; 14(3): 875 - 882.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. Chen, J. Wang, K. Hope, L. Jin, J. Dick, R. Cameron, J. Brandwein, M. Minden, and R. M. Reilly
Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells
J. Nucl. Med., May 1, 2006; 47(5): 827 - 836.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. S. Jaggi, S. V. Seshan, M. R. McDevitt, K. LaPerle, G. Sgouros, and D. A. Scheinberg
Renal Tubulointerstitial Changes after Internal Irradiation with {alpha}-Particle-Emitting Actinium Daughters
J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2677 - 2689.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh Jaggi, J.
Right arrow Articles by Scheinberg, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh Jaggi, J.
Right arrow Articles by Scheinberg, D. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online